Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LEXX)

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Accesswire 1 day ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

TheNewsWire 1 day ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

TheNewsWire 7 days ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

TheNewsWire 8 days ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

TheNewsWire November 7, 2024

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

TheNewsWire October 24, 2024

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

TheNewsWire October 22, 2024

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TheNewsWire October 16, 2024

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TheNewsWire October 15, 2024
View More News ››

Opinion & Analysis (NDAQ:LEXX)

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

Featured Submission March 10, 2021

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

Stockhouse Editorial December 2, 2020

VIDEO: Technology for Healthier Ingestion of Drugs & Molecules

BTV-Business Television March 26, 2019

VIDEO: Ingesting Instead of Inhaling Could Save 60,000 Lives a Year

BTV-Business Television March 5, 2019

Capitalizing on the growing need of a merchant bank for global medical cannabis companies

Stockhouse Editorial September 25, 2018

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle

Streetwise Reports February 14, 2018
View More Opinion ››

Bullboard Posts (NDAQ:LEXX)

RE:New Press Release - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

CBD with Lexaria tech outperforms weight loss drug Rybelsus in mice. Hope it's the same in human studies.
lscfa - 1 day ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (accesswire.com)
shawk - October 10, 2024

Lexaria on Youtube

Game-Changing Oral GLP-1 Coming Soon! (youtube.com) About the 8 minute mark.
shawk - October 6, 2024

Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continu

Breaking News: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing...
whytestocks - September 17, 2024

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse

Breaking News: $LEXX Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral...
whytestocks - August 29, 2024

InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX)

Breaking News: $LEXX InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results...
whytestocks - August 21, 2024
View more Bullboard ››

Silvercorp Metals Inc.

Silvercorp Metals Inc.

Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and ...
View More »